[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"misophonia-treatment\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:misophonia-treatment":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100613814","early-phase-1-propranolol-for-misophonia-100613814",false,"NCT07271485","Propranolol for Misophonia","Randomized, Placebo-Controlled Pilot Study of Propranolol for Treating Misophonia","Inclusion Criteria:\n\n* Age 18-65.\n* Able to complete study visit(s) in Littleton, CO.\n* Able to give informed consent.\n* Participant reports clinically significant misophonia symptoms, as determined by answers on the standardized \"Misophonia Trigger Screening Questions for Participants\" form (described separately in the protocol). Specifically, participants must demonstrate relevant misophonia trigger responses that meet pre-specified minimum severity criteria detailed on this form.\n* A-MISO-S rating scale severity criterion: Participants must score at least a moderate (\"2\") or higher on question 2 and question 3 of the Amsterdam Misophonia Scale (A-MISO-S) at screening, since this indicates clinically meaningful misophonia severity for study eligibility.\n* Able to communicate misophonic distress in writing and reasonably participate in our outpatient clinical setting, meaning able to tolerate being in this outpatient clinical setting, follow the clinic rules for all patients and guests, and respond in an understandable fashion to questions administered to them.\n* Must agree to follow study clinician advice and seek additional care outside of this clinic if advised (e.g., if advised to seek help from emergency services for a potentially serious adverse reaction).\n* English fluency\n\nExclusion Criteria:\n\n* Current use of scheduled propranolol for any condition.\n* Any of the known contraindications for taking propranolol:\n* cardiogenic shock\n* sinus bradycardia (\\\u003C50 bpm)\n* greater than first degree heart block\n* BP below 90\u002F60\n* asthma \u002F bronchial asthma that requires treatment or medication, and\u002For has caused clinical concerns within the last 5 years\n* Other heart conditions that require ongoing medical treatment\n* Participants with any of the following relative contraindications for taking propranolol:\n* participants who have active anorexia, purging, or who are underweight (\\\u003C18.5 BMI)\n* Active drug or alcohol use within the last 48 hours prior to study participation, or active drug withdrawals\n* A history of untreated diabetes or other endocrine disorders that could be harmed by exposure to propranolol\n* history of cardiovascular disease or stroke, or symptomatic blood disorders such as anemia\n* history of any other severe physical or neurological conditions that may affect their ability to participate in the study\n* Participants with liver or kidney disease that would be affect or be affected by the study drug\n* Participants may, depending on the circumstances as decided by the study clinician, be excluded for any of the following conditions that may have adverse reactions to propranolol, including: Raynaud disease or other peripheral vascular disease, Pheochromocytoma, Psoriasis, Thyroid disease (untreated, and affected by propranolol), Unexplained dizziness, Oxygen level below 91%, Respirations below 12 or above 20\n* Participants taking any other medications that could interfere with the effects of propranolol, as determined by the study clinician (e.g. other beta blockers, alpha blockers,prazosin, clonidine, guanfacine, diuretics, calcium channel blockers, acute us of anti-anxiety medications; other medications that interfere with the adrenergic system; or medications that have a significant effect on propranolol's pharmacology that would normally affect dosing in clinical practice\n* Allergy or sensitivity to propranolol, placebo ingredients, and\u002For capsule ingredients.\n* Pregnant or nursing.\n* Any of the following in 30 days prior to enrollment: active psychosis, suicidal\u002F self-harming \u002F homicidal thoughts, bipolar mania, panic attacks, traumatic dissociation, Post-Traumatic Stress Disorder (PTSD) flashbacks, or psychiatric hospitalization.\n* Participant self-reports or clinical interview identifies any misophonia-triggered reactions within the past year that posed a significant risk to health or safety, including suicidal or homicidal ideation, or uncontrolled physical behaviors (e.g., self-injury, aggression toward others, throwing objects, screaming, or fleeing uncontrollably). This criterion is assessed via direct structured questioning during participant screening interviews and review of participant self-reports on standardized screening questionnaires.\n* Misophonia trigger symptoms are determined by a medical provider to be better explained by a condition other than Misophonia, such as hyperacusis or phonophobia.\n* Inability to hear routine sounds and communication (ie severe hearing impairment), only if it interferes with ability to hear the misophonia triggers on the video.\n* Participants who are triggered by the sound of water running or a car alarm (our control videos)","ALL","18 Years","65 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24],"EARLY_PHASE1","The primary goal of this study is to investigate whether a one-time dose of 20 mg oral propranolol can temporarily reduce the adverse emotional and physical symptoms triggered by misophonia.\n\nThe secondary goals of this study are:\n\n1. Determine potential predictors of response to propranolol treatment, including demographic factors, baseline symptom severity, psychometric instrument item responses, and physiological characteristics.\n2. Evaluate the safety and tolerability of propranolol in individuals with misophonia.",[27,28,29],"Misophonia","Propanolol","Misophonia Treatment","RECRUITING","2025-12-05",{"date":33,"type":34},"2025-12-09","ACTUAL",{"date":36,"type":21},"2025-12-19",{"date":38,"type":21},"2026-12-19",{"name":40,"class":41},"Bloom Mental Health, LLC","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":54,"conditions":55,"keywords":60,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":4},"100576465","the-efficacy-of-lavender-herbal-tea-in-misophonia-100576465","NCT06785649","The Efficacy of Lavender Herbal Tea in Misophonia","The Effect of Lavender Herbal Tea on the Mental Health of Individuals With Misophonia: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Reporting at least three trigger sounds\n* Assessed by a specialist psychiatric nurse and a psychiatrist as humophonia based on the diagnostic criteria for humophonia established by Schröder et al. (2013)\n* Individuals aged 18 and over\n\nExclusion Criteria:\n\n* Allergy to any herbal tea, food or medicine\n* Psychiatric illness or chronic illness\n* Taking psychiatric medication (such as anxiolytics, and antidepressants)\n* Regular use of medication (such as antihypertensive, antidiabetic)\n* Regular use of herbal teas or complementary medicines\n* Tinnitus and\u002For hyperacusis",{"count":51,"type":21},60,[53],"NA","Misophonia is a disorder characterized by a high level of annoyance with certain sounds. Exposure to these sounds causes physical symptoms characterized by anger, aggression, helplessness, overwhelm, and stimulation of the sympathetic nervous system. These emotional and physical reactions can lead to a decline in family relationships, work and school productivity, withdrawal from social relationships, and even suicide. There is limited empirical evidence evaluating the efficacy of therapeutic approaches to misophonia. This limited empirical evidence consists of pharmacological agents such as selective serotonin reuptake inhibitors, stimulants, antipsychotics, and β-Blockers, as well as cognitive behavioral therapy, acceptance and commitment therapy, and dialectical behavior therapy. Complementary therapies are important because of their potential efficacy, tolerability, possible non-interference, and low cost. The fact that lavender has anxiolytic, antidepressant, neuroprotective, and anti-inflammatory properties may affect the emotional and physical responses elicited by misophonia. Therefore, within the scope of the study, misophonia individuals will be divided into two groups; one group will use lavender tea for 14 days and the other group will form a waiting list. The study data will be collected by 'Information Collection Form', 'Misophonia Scale', 'Beck Depression Inventory-II', 'Anxiety Rating Scale', and 'Trait Anger Scale'. SPSS 25.0 software will be used to analyze the data obtained from the research. Considering the limitations of therapeutic approaches for misophonia, testing the effectiveness of lavender in reducing misophonia symptoms will make an important contribution to the literature.",[27,29,56,57,58,59],"Anxiety","Depression","Anger","Complementary Medicine",[61,62,63,64,65],"misophonia","anxiety","depression","anger","lavender","NOT_YET_RECRUITING","2025-01-19",{"date":69,"type":34},"2025-01-21",{"date":71,"type":21},"2025-02-01",{"date":73,"type":21},"2025-02-28",{"name":75,"class":41},"Sakarya University"]